the aid library

LIST OPTIONS

Filter

1622

Sort by:

Direction:

Download (838)

View PDF (1362)

Malawi: Assessment of the Logistics and Supply Chain Management of Anti-TB Medicines

Chana, R USAID (2009) C1

Download (274)

View PDF (429)

Managing TB Medicines at the Primary Level

USAID; Management Sciences for Health (2008) C1

April 2008

Download (369)

View PDF (998)

India: Guidelines for Setting up Blood Storage Centres

National AIDS Control Organisation (NACO), Ministry of Health and Family Welfare, Government of India; National Blood Transfusion Council (NBTC) (2007) C1

Download (1403)

View PDF (692)

Sierra Leone: Supply chain assessment for ARV drugs and HIV test kits

Allers, Claudia, Timothy O’Hearn, and Meba Kagone USAID (2007) C1

Download (2345)

View PDF (2461)

National Guidelines for Diagnosis and Treatment of Malaria

Ministry of Health and Social Welfare, The United Republic of Tanzania (2006) C1

Download (1158)

View PDF (2024)

Recommendations for Inactivated Rabies Vaccine for Human Use Produced in Cell Substrates and Embryonated Eggs

WHO WHO (2005)

Download (1595)

View PDF (975)

Zimbabwe: Medicines and Allied Substances Control (General) Regulations

Government of Zimbabwe (2004) C2

Statutory Instrument 150 of 1991 | S.I. 150 of 1991 | Amended by S.I.’ s 298/93, 61/94, 319/94, 199/98, 256/98, 36/99, 24/2001 and 257/2002, 105 and 222 /2004

Download (1008)

View PDF (1987)

Ghana national drug policy

Ministry of Health, Ghana (2004) C1

Download (411)

View PDF (761)

Guidelines on Drug Registration Applications in Botswana

Drugs Advisory Board, Republic of Botswana (Gabarone, Botswana) (2000)

First Revised Edition March 2000

Download (2132)

View PDF (2212)

Guidelines for Safe Disposal of Unwanted Pharmaceuticals in and after Emergencies

World Health Organization WHO (1999) C_WHO

Download (31)

View PDF (43)

Worldwide rates of diagnosis and effective treatment for cystic fibrosis

Guo, J.; Garratt, A.; Hill, A. Journal of Cystic Fibrosis (2022) CC

Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transforma... more

Download (25)

View PDF (26)

Under- and over-diagnosis of COPD: a global perspective

Ho T., Cusack R.P., Chaudhary N. et al. Breathe, part of the European Respiratory Society (ERS) (2019) CC2

The article "Under- and over-diagnosis of COPD: a global perspective" reviews the worldwide variation in the prevalence of chronic obstructive pulmonary disease (COPD) and issues related to its misdiagnosis. It highlights that COPD is under-diagnosed due to factors such as limited access to spiromet... more

Download (25)

View PDF (34)

Epidemiology and Challenges of Managing COPD in sub-Saharan Africa

Magitta, N.F.; Sciences, A. Acta Scientific Medical Sciences (2018) CC2

There is paucity of data on the burden and specific drivers operative in the pathogenesis of chronic obstructive pulmonary disease (COPD) in the African setting and populations. Lack of awareness and inadequate knowledge on the aetio-pathogenesis of the disease together with inadequate capacity for ... more

Download (37)

View PDF (33)

The burden of severe asthma in sub-Saharan Africa: Findings from the African Severe Asthma Project

Kirenga, B.J.; Chakaya, J.; Yimer, G. et al. Journal of Allergy and Clinical Immunology: Global (2024) CC

Severe asthma is associated with high morbidity, mortality, and health care utilization, but its burden in Africa is unknown. This article wants to determine the burden (prevalence, mortality, and activity and work impairment) of severe asthma in 3 countries in East Africa: Uganda, Kenya, and Ethio... more

Download (39)

View PDF (41)

Guidelines for the management of chronic asthma in adolescents and adults

Lalloo, U.; Wong, M.; Abdool-Gaffar, S. et al. South African Family Practice (2007) CC

Asthma prevalence is increasing worldwide and surveys indicate that the majority of patients in developed and developing countries do not receive optimal care and are therefore not well controlled. The aim of these guidelines is to promote a better standard of treatment based on advances in the unde... more

Download (60)

View PDF (109)

Asthma morbidity in Africa: Is it time to act to achieve asthma care for all?

Thembelihle Hlophe, S.; Stolbrink, M.; Govender, K.; et al. (2023) CC2

As we approach World Asthma Day on the May 2, 2023, we reflect on the theme “ Asthma Care for All”. Prevalence of Asthma is increasing amongst children, adolescents and adults. Under-diagnosis, underutilization of inhaled corticosteroids, inaccessibility of treatment, and unaffordability of medi... more

Download (38)

View PDF (118)

Proposed Strategies to Improve Adult Asthma Management in Egypt: Expert Review and Recommendations

Hosny, H.; Madkour, A.; Hantera, M.; et al. (2022) CC2

Several challenges face asthma management in Egypt, including the high percentage of uncontrolled patients, inadequate compliance, and overuse of short-acting beta-agonists (SABAs) leading to increased asthma-related morbidity and mortality. In this regard, the recent Global Initiative for Asthma (G... more

Download (47)

View PDF (114)

Asthma management in low and middle income countries: case for change

Mortimer, K.; Reddel, H. K.; Pitrez, P. M.; et al. (2022) CC2

Asthma is the most common noncommunicable disease in children, and among the most common in adults. According to the most recent estimates from the Global Asthma Network Phase I study, around one in 10 children and adults have symptoms of asthma and one in 20 school-aged children have severe asthma ... more

Download (45)

View PDF (45)

The Burden of Pediatric Asthma

Ferrante, G.; La Grutta, S. Frontiers in Pediatrics (2018) CC

Asthma is the most common chronic disease in children, imposing a consistent burden on health system. In recent years, prevalence of asthma symptoms became globally increased in children and adolescents, particularly in Low-Middle Income Countries (LMICs). Host (genetics, atopy) and environmental fa... more

Download (261)

View PDF (356)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more